{"organizations": [], "uuid": "d1ab3793a4aee6a497c1399a9be2903871abb09a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/20/globe-newswire-altimmune-to-announce-year-end-2017-financial-results-on-march-29.html", "country": "US", "domain_rank": 767, "title": "Altimmune to Announce Year End 2017 Financial Results on March 29", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-20T23:01:00.000+02:00", "replies_count": 0, "uuid": "d1ab3793a4aee6a497c1399a9be2903871abb09a"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/20/globe-newswire-altimmune-to-announce-year-end-2017-financial-results-on-march-29.html", "ord_in_thread": 0, "title": "Altimmune to Announce Year End 2017 Financial Results on March 29", "locations": [], "entities": {"persons": [], "locations": [{"name": "md.", "sentiment": "none"}, {"name": "gaithersburg", "sentiment": "none"}, {"name": "altimmune", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "GAITHERSBURG, Md., March 20, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended December 31, 2017 before the market open and host a conference call on Thursday, March 29.\nConference Call Details Date: Thursday, March 29 Time: 8:30am Eastern Time Domestic: 866-548-4713 International: 323-794-2093 Conference ID: 6280732 Webcast: http://public.viavid.com/index.php?id=128569 Replays, Available through April 12th: Domestic: 844-512-2921 International: 412-317-6671 Replay PIN: 6280732 About Altimmune\nAltimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.\nContacts:\nBill Enright\nPresident and CEO\nPhone: 240-654-1450\nenright@altimmune.com\nAshley Robinson\nLifeSci Advisors, LLC\n617-535-7742\narr@lifesciadvisors.com\nSource:Altimmune, Inc.", "external_links": ["http://public.viavid.com/index.php?id=128569", "https://www.globenewswire.com/NewsRoom/AttachmentNg/2592324d-a5f2-47e7-8acb-a53f8e235e88"], "published": "2018-03-20T23:01:00.000+02:00", "crawled": "2018-03-20T22:25:12.001+02:00", "highlightTitle": ""}